An MRC Cleanroom in Poland is to be used for the NOVAVAX Covid-19 Vaccine.

MRC congratulates its client Mabion for signing an agreement to manufacture Novavax's COVID-19 vaccine. MRC is proud to have been involved in the construction of Mabion's cleanroom facility. This facility, spread over two floors, is utilising the MRC GRP cleanroom panelling system.

Mabion SA signed a framework agreement with Novavax for the transfer of the U.S. company’s COVID-19 vaccination technology. Mabion will become the first Polish company engaged in the worldwide effort to supply sufficient quantities of COVID-19 vaccines to serve the global need. The company will produce technical batches of antigen for Novavax.

In late January, Novavax announced that its vaccine candidate had proved to be 89.3-percent effective at preventing COVID-19 in participants in its phase 3 clinical trial in the UK, and around 86-percent effective at protecting against the UK variant.

Mabion SA's MRC cleanroom is now the second MRC cleanroom being utilised directly in the production of COVID-19 vaccines.

For queries and questions, visit